Show simple item record

dc.contributor.authorBegum, P
dc.contributor.authorGoldin, RD
dc.contributor.authorPossamai, LA
dc.contributor.authorPopat, S
dc.date.accessioned2021-11-25T14:42:20Z
dc.date.available2021-11-25T14:42:20Z
dc.identifier.citationJTO clinical and research reports, 2021, 2 (9), pp. 100213 - ?
dc.identifier.issn2666-3643
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4901
dc.identifier.eissn2666-3643
dc.identifier.doi10.1016/j.jtocrr.2021.100213
dc.description.abstractSotorasib is a first-in-class small molecule that irreversibly inhibits KRAS G12C, locking it in an inactive state, inhibiting oncogenic signaling, and inducing a proinflammatory microenvironment. Here, we report the first case of life-threatening hepatitis in a patient with NSCLC shortly after commencing sotorasib, in which biopsy result was consistent with checkpoint inhibitor (CPI) immune-related adverse event, implicating sotorasib as being able to trigger CPI immune hepatitis. Given the large proportion of patients potentially treatable with sequential sotorasib after CPI, coupled with limited trial data, sotorasib-triggered CPI immune-related hepatitis should be considered in patients with sotorasib hepatotoxicity.
dc.formatElectronic-eCollection
dc.format.extent100213 - ?
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleSevere Immune Checkpoint Inhibitor Hepatitis in <i>KRAS</i> G12C-Mutant NSCLC Potentially Triggered by Sotorasib: Case Report.
dc.typeJournal Article
dcterms.dateAccepted2021-07-19
rioxxterms.versionVoR
rioxxterms.versionofrecord10.1016/j.jtocrr.2021.100213
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfJTO clinical and research reports
pubs.issue9
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology/Thoracic Oncology (hon.)
pubs.publication-statusPublished
pubs.volume2
pubs.embargo.termsNot known
icr.researchteamThoracic Oncology
dc.contributor.icrauthorPopat, Sanjayen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0